XBIT News and Press, XBiotech Inc. From 09/27/23

Nabriva Therapeutics plc (NBRVF) is expected to report for Q2 2023 JFE Holdings, Inc. (JFEEF) is expected to report for Q1 2024 Superior Gold Inc (SUPGF) is expected to report for Q2 2023 S&W Seed Company (SANW) is expected to report $-0.09 for Q4 2023 Jefferies Financial Grou...

AUSTIN, Texas, Sept. 26, 2023 (GLOBE NEWSWIRE) -- XBiotech Inc. (NASDAQ: XBIT) Announces that Hutrukin is being developed by XBiotech as a breakthrough therapy to reduce brain injury after stroke. The last subject in a randomized, open-label, placebo-controlled Phase I dose escalation clinic...

Westbury Bancorp Inc (WBBW) is expected to report for quarter end 2023-06-30 Sumitomo Heavy Industries Ltd. ADR (SOHVY) is expected to report for Q1 2024 Belgravia Hartford Capital Inc (BLGVF) is expected to report for Q2 2023 Yasheng Group (HERB) is expected to report for Q2 2023 ...

Software AG ADR (STWRY) is expected to report for Q2 2023 Dai Nippon Printing Co Ltd ADR (DNPLY) is expected to report for quarter end 2023-06-30 Coffee Holding Co. Inc. (JVA) is expected to report for Q1 2024 Calloway`s Nursery, Inc. (CLWY) is expected to report for Q2 2023 Home ...

Sportsman's Warehouse Holdings Inc. (SPWH) is expected to report $0.02 for Q2 2024 Screen Holdings Co. Ltd. (DINRF) is expected to report for Q1 2024 Bionik Laboratories Corp (BNKL) is expected to report for Q1 2024 Atento S.A. (ATTOF) is expected to report for Q2 2023 Akoustis Te...

XBiotech Inc. (XBIT) is expected to report for quarter end 2023-06-30

AUSTIN, Texas, Aug. 30, 2023 (GLOBE NEWSWIRE) -- XBiotech Inc. announced today completion of enrollment of the Phase II portion of its 1-BETTER study—a Phase I/II randomized, double-blind, placebo-controlled clinical study for Natrunix in combination with chemotherapy for treating pancreat...

AUSTIN, Texas, Aug. 08, 2023 (GLOBE NEWSWIRE) -- XBiotech Inc. (NASDAQ: XBIT) today began treating the first patient in a phase II, double-blind, placebo-controlled, randomized clinical study to evaluate Natrunix as a new treatment for Arthritis. Natrunix blocks a key cause of inflammation involv...

2023-07-10 04:56:16 ET Summary The new July 2023 selections are the current top positive/negative forensic stocks based on combined scores from four different forensic algorithms. Both the 2022 January Positive Forensic portfolio beat the S&P 500 by +6.59% and the Negative For...

AUSTIN, Texas, May 22, 2023 (GLOBE NEWSWIRE) -- XBiotech Inc. (NASDAQ: XBIT) today reports that the FDA’s Division of Rheumatology has authorized the Company to initiate a Phase II clinical study to test Natrunix™ as a treatment for Rheumatoid Arthritis. The randomized, d...